Tirzepatide represents a groundbreaking treatment agent for individuals facing type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://barbaracomd040853.blogoxo.com/40947970/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist